A Rational Approach to the Treatment of Acute Pulmonary Embolism

Literature Cited

1. 1.

   Farmakis IT, Valerio L, Bikdeli B, et al. 2022.. Annual mortality related to pulmonary embolism in the U.S. before and during the COVID-19 pandemic. . J. Am. Coll. Cardiol. 80:(16):1579–81
   [Google Scholar]
2. 2.

   Kobayashi T, Pugliese S, Sethi SS, et al. 2024.. Contemporary management and outcomes of patients with high-risk pulmonary embolism. . J. Am. Coll. Cardiol. 83:(1):35–43
   [Google Scholar]
3. 3.

   Smith SB, Geske JB, Kathuria P, et al. 2016.. Analysis of national trends in admissions for pulmonary embolism. . Chest 150:(1):35–45
   [Google Scholar]
4. 4.

   Konstantinides SV, Meyer G, Becattini C, et al. 2020.. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). . Eur. Heart J. 41:(4):543–603
   [Google Scholar]
5. 5.

   Giri J, Sista AK, Weinberg I, et al. 2019.. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association. . Circulation 140:(20):e774–801
   [Google Scholar]
6. 6.

   O'Connell C. 2015.. How I treat incidental pulmonary embolism. . Blood 125:(12):1877–82; quiz 2009
   [Google Scholar]
7. 7.

   Arrigo M, Huber LC. 2020.. Pulmonary embolism and heart failure: a reappraisal. . Card. Fail. Rev. 7::e03
   [Google Scholar]
8. 8.

   Harjola VP, Mebazaa A, Čelutkienė J, et al. 2016.. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. . Eur. J. Heart Fail. 18:(3):226–41
   [Google Scholar]
9. 9.

   Fang MC, Reynolds K, Fan D, et al. 2023.. Clinical outcomes of direct oral anticoagulants versus warfarin for extended treatment of venous thromboembolism. . JAMA Netw. Open 6:(8):e2328033
   [Google Scholar]
10. 10.

    Agnelli G, Buller HR, Cohen A, et al. 2013.. Oral apixaban for the treatment of acute venous thromboembolism. . N. Engl. J. Med. 369:(9):799–808
    [Google Scholar]
11. 11.

    Chatterjee S, Chakraborty A, Weinberg I, et al. 2014.. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. . JAMA 311:(23):2414–21
    [Google Scholar]
12. 12.

    Zhang Z, Zhai ZG, Liang LR, et al. 2014.. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis. . Thromb. Res. 133:(3):357–63
    [Google Scholar]
13. 13.

    Avgerinos ED, Jaber W, Lacomis J, et al. 2021.. Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism: the SUNSET sPE Trial. . JACC Cardiovasc. Interv. 14:(12):1364–73
    [Google Scholar]
14. 14.

    Piazza G, Hohlfelder B, Jaff MR, et al. 2015.. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: The SEATTLE II Study. . JACC Cardiovasc. Interv. 8:(10):1382–92
    [Google Scholar]
15. 15.

    Kuo WT, Banerjee A, Kim PS, et al. 2015.. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): initial results from a prospective multicenter registry. . Chest 148:(3):667–73
    [Google Scholar]
16. 16.

    Goldberg JB, Giri J, Kobayashi T, et al. 2023.. Surgical management and mechanical circulatory support in high-risk pulmonary embolisms: historical context, current status, and future directions: a scientific statement from the American Heart Association. . Circulation 147:(9):e628–47
    [Google Scholar]
17. 17.

    Goldberg JB, Spevack DM, Ahsan S, et al. 2022.. Comparison of surgical embolectomy and veno-arterial extracorporeal membrane oxygenation for massive pulmonary embolism. . Semin. Thorac. Cardiovasc. Surg. 34:(3):934–42
    [Google Scholar]
18. 18.

    Mirambeaux R, León F, Bikdeli B, et al. 2019.. Intermediate-high risk pulmonary embolism. . TH Open 3:(4):e356–63
    [Google Scholar]
19. 19.

    Lehr A, Guichet P, Garimella B, et al. 2023.. Impact of time to intervention on catheter-directed therapy for pulmonary embolism. . Crit. Care Explor. 5:(1):e0828
    [Google Scholar]
20. 20.

    Rawal A, Ardeshna D, Hesterberg K, et al. 2019.. Is there an optimal “door to cath time” in the treatment of acute pulmonary embolism with catheter-directed thrombolysis?. Ann. Transl. Med. 7:(17):419
    [Google Scholar]
21. 21.

    Klok FA, Piazza G, Sharp ASP, et al. 2022.. Ultrasound-facilitated, catheter-directed thrombolysis versus anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study. . Am. Heart J. 251::43–53
    [Google Scholar]
22. 22.

    Giri J, Mahfoud F, Gebauer B, et al. 2024.. PEERLESS II: a randomized controlled trial of large-bore thrombectomy versus anticoagulation in intermediate-risk pulmonary embolism. . JSCAI 3:(6):101982
    [Google Scholar]
23. 23.

    Gonsalves CF, Gibson CM, Stortecky S, et al. 2023.. Randomized controlled trial of mechanical thrombectomy versus catheter-directed thrombolysis for acute hemodynamically stable pulmonary embolism: rationale and design of the PEERLESS study. . Am. Heart J. 266::128–37
    [Google Scholar]
24. 24.

    Bikdeli B, Chatterjee S, Desai NR, et al. 2017.. Inferior vena cava filters to prevent pulmonary embolism: systematic review and meta-analysis. . J. Am. Coll. Cardiol. 70:(13):1587–97
    [Google Scholar]
25. 25.

    Jia Z, Wu A, Tam M, et al. 2015.. Caval penetration by inferior vena cava filters: a systematic literature review of clinical significance and management. . Circulation 132:(10):944–52
    [Google Scholar]